Reference Source

Penalty for any responsible person that violates a requirement of 21 U.S.C. 355(o) (post-marketing studies, clinical trials, labeling), 21 U.S.C. 355(p) (risk evaluation and mitigation (REMS)), or 21 U.S.C. 355 -1 (REMS)

For Penalty for any responsible person that violates a requirement of 21 U.S.C. 355(o) (post-marketing studies, clinical trials, labeling), 21 U.S.C. 355(p) (risk evaluation and mitigation (REMS)), or 21 U.S.C. 355 -1 (REMS), agency is HHS; statutory authority is 333(f)(4)(A)(i); maximum penalty is 377,701, recorded from its source on 2026-08-10.

Agency
HHS our reading
Violation
Penalty for any responsible person that violates a requirement of 21 U.S.C. 355(o) (post-marketing studies, clinical trials, labeling), 21 U.S.C. 355(p) (risk evaluation and mitigation (REMS)), or 21 U.S.C. 355 -1 (REMS) verified
Statutory authority
333(f)(4)(A)(i) verified
Maximum penalty
377,701 verified
Sourceecfr.gov
Verified
Review by
DatasetFederal civil penalty maximums — current inflation-adjusted amounts across agencies

Values marked our reading are our classification of what the source says — the source does not print them in those words. The quote below is the evidence for each one; judge it yourself.

What the source says

333(f)(4)(A)(i) | | FDA | Penalty for any responsible person that violates a requirement of <https://www.govinfo.gov/link/uscode/21/355> 21 U.S.C. 355(o) (post-marketing studies, clinical trials, labeling), <https://www.govinfo.gov/link/uscode/21/355> 21 U.S.C. 355(p) (risk evaluation and mitigation (REMS)), or <https://www.govinfo.gov/link/uscode/21/355> 21 U.S.C. 355 -1 (REMS) | 2024 | 368,137 | 377,701

ecfr.gov, retrieved 2026-08-10

Source

Last verified against source: . Due for re-check by . This page as Markdown · OKF bundle · full dataset as JSON.